Allozymes secures $15M Series A funding to expand its Enzyme Screening Technology nextdigitalhealth.com

Allozymes secures $15M Series A funding to expand its Enzyme Screening Technology

Allozymes, a pioneering biotech startup, has just closed a remarkable $15 million Series A funding round, propelling its transformative enzyme screening technology into the spotlight. This investment marks a significant milestone for the company, positioning it to evolve from a valuable service provider to a global leader in bio-based chemical innovation.

Founded in 2021 by CEO Peyman Salehian, Allozymes has experienced exponential growth since its humble beginnings with less than five staff members and a modest lab space of just a thousand square feet. Fast forward to the present day, the company boasts a team of 32 experts spanning across the United States, Europe, and Singapore, with a lab space expanded fifteenfold to accommodate its groundbreaking research.

https://nextdigitalhealth.com/funding-news/allozymes-secures-15m-series-a-funding-to-expand-its-enzyme-screening-technology/